Research presented at the American Diabetes Association's 73rd Scientific Sessions showed the one-year drug discontinuation rate among type 2 diabetes patients was 89% in those taking a glucagon-like peptide-1 agonist, 82% in those who took a dipeptidyl-peptidase-4 inhibitor and 84% in those treated with other diabetes drugs. The findings highlight the need for better persistence with GLP-1 agonist therapy, the lead researcher said.

Related Summaries